Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 308

1.

Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia?

Raebel MA, McClure DL, Chan KA, Simon SR, Feldstein AC, Lafata JE, Andrade SE, Gunter MJ, Nelson WW, Roblin D, Platt R.

Ann Pharmacother. 2007 Feb;41(2):193-200. Epub 2007 Feb 6.

PMID:
17284506
2.

Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.

Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein A, Andrade SE, Lafata JE, Roblin D, Davis RL, Gunter MJ, Platt R.

Pharmacoepidemiol Drug Saf. 2007 Jan;16(1):55-64.

PMID:
16470693
3.

The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.

Shah KB, Rao K, Sawyer R, Gottlieb SS.

J Am Coll Cardiol. 2005 Sep 6;46(5):845-9.

4.

How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?

Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D.

J Card Fail. 2004 Aug;10(4):297-303.

PMID:
15309695
5.
6.

Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.

Tamirisa KP, Aaronson KD, Koelling TM.

Am Heart J. 2004 Dec;148(6):971-8.

PMID:
15632880
8.

Safety of spironolactone use in ambulatory heart failure patients.

Lopes RJ, Lourenço AP, Mascarenhas J, Azevedo A, Bettencourt P.

Clin Cardiol. 2008 Nov;31(11):509-13. doi: 10.1002/clc.20284.

9.
10.

Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients.

Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein AC, Gunter MJ, Lafata JE, Harrold L, Nelson WW, Platt R.

Ann Pharmacother. 2006 Mar;40(3):386-91. Epub 2006 Feb 14.

PMID:
16478808
11.

Hyperkalemia during spironolactone use in patients with decompensated heart failure.

Lima MV, Ochiai ME, Cardoso JN, Morgado PC, Munhoz RT, Barretto AC.

Arq Bras Cardiol. 2008 Sep;91(3):177-82, 194-9. English, Portuguese.

12.

New prescriptions of spironolactone associated with angiotensin-converting-enzyme inhibitors and/or angiotensin receptor blockers and their laboratory monitoring from 2001 to 2008: a population study on older people living in the community in Italy.

Bilotta C, Franchi C, Nobili A, Nicolini P, Djade CD, Tettamanti M, Fortino I, Bortolotti A, Merlino L, Vergani C.

Eur J Clin Pharmacol. 2013 Apr;69(4):909-17. doi: 10.1007/s00228-012-1401-8. Epub 2012 Sep 21.

PMID:
22996075
13.

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA.

N Engl J Med. 2004 Aug 5;351(6):543-51.

14.

Laboratory monitoring of patients treated with antihypertensive drugs and newly exposed to non steroidal anti-inflammatory drugs: a cohort study.

Fournier JP, Lapeyre-Mestre M, Sommet A, Dupouy J, Poutrain JC, Montastruc JL.

PLoS One. 2012;7(3):e34187. doi: 10.1371/journal.pone.0034187. Epub 2012 Mar 27.

15.

Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.

Masoudi FA, Gross CP, Wang Y, Rathore SS, Havranek EP, Foody JM, Krumholz HM.

Circulation. 2005 Jul 5;112(1):39-47. Epub 2005 Jun 27.

16.

Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure.

Cavallari LH, Groo VL, Viana MA, Dai Y, Patel SR, Stamos TD.

Pharmacotherapy. 2010 Jan;30(1):1-9. doi: 10.1592/phco.30.1.1.

PMID:
20030467
17.

Safety of spironolactone use in ambulatory heart failure patients.

Kandula P, Shah R.

Clin Cardiol. 2009 Jun;32(6):347-8. doi: 10.1002/clc.20597. No abstract available.

18.

Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates.

Raebel MA, Ross C, Cheetham C, Petersen H, Saylor G, Smith DH, Wright LA, Roblin DW, Xu S.

Pharmacoepidemiol Drug Saf. 2010 Jan;19(1):19-25. doi: 10.1002/pds.1882.

PMID:
19937982
19.

The safety of spironolactone treatment in patients with heart failure.

Anton C, Cox AR, Watson RD, Ferner RE.

J Clin Pharm Ther. 2003 Aug;28(4):285-7.

PMID:
12911680
20.

Clinical factors associated with hyperkalemia in patients with congestive heart failure.

Ramadan FH, Masoodi N, El-Solh AA.

J Clin Pharm Ther. 2005 Jun;30(3):233-9.

PMID:
15896240

Supplemental Content

Support Center